Core Viewpoint - Huaheng Biological has demonstrated significant growth in its financial performance for Q3 2025, with a notable increase in revenue and net profit, positioning itself as a leader in the bio-based product market [1][2][3] Financial Performance - In Q3 2025, the company achieved revenue of 704 million yuan, a year-on-year increase of 34.73% - The net profit attributable to shareholders reached 52.73 million yuan, up 161.22% year-on-year - The net profit after deducting non-recurring items was 52.21 million yuan, reflecting a growth of 187.98% - The net cash flow from operating activities was 40.01 million yuan, an increase of 84.95% year-on-year - For the first three quarters, total revenue amounted to 2.194 billion yuan, representing a year-on-year growth of 42.53% [1] Market Position and Product Development - Huaheng Biological is recognized as one of the most comprehensive companies in the commercial application of bio-based products through synthetic biology technology - The company is the first globally to industrialize the anaerobic fermentation method for a series of amino acids, including L-Alanine and L-Valine - By 2024, the company holds the largest market share globally for L-Alanine and L-Valine [1][2] Global Expansion and Strategic Initiatives - The company has established a comprehensive product portfolio, including amino acids, vitamins, and other bio-based products, widely used across various industries such as animal nutrition, personal care, food and beverage, advanced materials, and plant nutrition - As of mid-2025, Huaheng Biological has formed stable long-term partnerships with over 768 clients across 85 countries in Asia, Europe, and the Americas, with some relationships lasting over 10 years - The global bio-based product market is expected to grow at a compound annual growth rate of 11.3% from 2024 to 2030, presenting significant growth opportunities for Huaheng Biological [2] Research and Development - The company places a strong emphasis on R&D innovation, with internal teams focused on market needs and developing cutting-edge synthetic biology technologies - Multiple high-end research platforms have been established, including independent R&D platforms, strategic cooperation platforms, and joint laboratories with major research institutions and universities - External research teams provide comprehensive support in areas such as strain construction, technology expansion, and innovation management, laying a solid foundation for product innovation and sustainable development [2] Listing and Capital Strategy - Recently, Huaheng Biological submitted an application for listing on the main board of the Hong Kong Stock Exchange to further its globalization strategy and consolidate its industry-leading position - A successful H-share issuance would help the company leverage international capital market resources, optimize its capital structure, and broaden financing channels to support stable growth [3]

Core Insights - The report highlights a significant decline in investment growth across various sectors, including infrastructure, services, manufacturing, and real estate, with fixed asset investment growth dropping to historical lows since mid-2025 [11][5][4] - The central bank's decision to resume government bond trading is expected to have a short-term positive impact, but the long-term effects may be neutral due to ongoing economic pressures [12][14] - China Shenhua's Q3 2025 performance showed stable growth despite challenges, with revenue and net profit exceeding market expectations, driven by cost control measures [4][13] Investment Growth Decline - Investment growth has sharply decreased, with fixed asset investment growth falling 9.2 percentage points to -6.5% in September 2025, marking the lowest point in five years [11] - Major sectors such as infrastructure, services, real estate, and manufacturing have all experienced declines, with specific drops of 13.1%, 11.1%, 9.3%, and 9.1% respectively [11] - The decline in construction and installation investment is identified as a primary factor contributing to the overall drop in fixed asset investment [11] Reasons for Investment Slowdown - The acceleration of debt resolution has occupied investment funds, explaining over half of the investment decline, with the issuance of special refinancing bonds significantly impacting available government investment funds [11][5] - Companies are being pressured to clear debts, which has further constrained their ability to invest, particularly affecting state-owned enterprises and the real estate sector [11] - A lack of new projects is also contributing to the investment slowdown, with new construction projects seeing a significant drop in growth [11] Policy Optimization Effects - Recent fiscal measures are aimed at alleviating the impact of debt resolution on investment, with targeted policies already showing some positive effects [11] - The report suggests that improving cash flow for enterprises through debt resolution could restore investment vitality, particularly for small and medium-sized enterprises [11] Company Performance Insights - China Shenhua reported a Q3 2025 revenue of CNY 750.42 billion, a 9.51% increase from Q2, although it represents a 13.10% year-on-year decline [13] - The company’s net profit for Q3 was CNY 144.11 billion, reflecting a 13.54% increase from the previous quarter but a 6.24% year-on-year decline [13] - The company maintains a high dividend payout ratio, planning to distribute CNY 194.71 billion in dividends for the first half of 2025, which is 79% of its net profit [13][17] Market Trends and Future Outlook - The report indicates that the market may experience a short-term boost from the resumption of government bond trading, but the overall economic environment remains challenging [12][14] - The performance of various sectors, including the coal and energy sectors, is under scrutiny, with expectations of continued pressure on profit margins due to fluctuating prices [17][18] - Companies are advised to focus on optimizing costs and enhancing operational efficiency to navigate the current economic landscape [17][18]

Core Insights - The best-performing fund managed by Yang Jiawen is the E Fund Balanced Preferred One-Year Holding Mixed A, with a quarterly net value increase of 31.29% as of Q3 2025 [1] Fund Performance Summary - E Fund Keri Mixed: - Size: 12.71 billion - Annualized Return: 10.91% - Q3 2025 Increase: 24.67% - Top Holding: Gongfu Lian [2] - E Fund Kahui Flexible Allocation Mixed: - Size: 6.91 billion - Annualized Return: 11.20% - Q3 2025 Increase: 28.20% - Top Holding: Desai Xiwai [2] - E Fund Reverse Investment Mixed A: - Size: 5.26 billion - Annualized Return: 5.17% - Q3 2025 Increase: 28.58% - Top Holding: Tencent Holdings [2] - E Fund Reverse Investment Mixed C: - Size: 2.46 billion - Annualized Return: 4.73% - Q3 2025 Increase: 28.46% - Top Holding: Tencent Holdings [2] - E Fund Balanced Preferred One-Year Holding Mixed A: - Size: 0.83 billion - Annualized Return: 11.73% - Q3 2025 Increase: 31.29% - Top Holding: Tencent Holdings [2] - E Fund Balanced Vision Mixed A2: - Size: 0.59 billion - Annualized Return: 24.56% - Q3 2025 Increase: 30.14% - Top Holding: Tencent Holdings [2] - E Fund Balanced Preferred - Annual Holding Mixed C: - Size: 0.09 billion - Annualized Return: 11.18% - Q3 2025 Increase: 31.12% - Top Holding: Yingxun Holdings [2] Investment Strategy and Performance - Yang Jiawen has achieved a cumulative return of 113.78% during his tenure managing the E Fund Keri Mixed, with an average annualized return of 10.17% [2] - The fund has made 87 adjustments to its top holdings, with a success rate of 54.02% for profitable trades [2] Notable Stock Adjustments - Example of Aishi Chuangneng: - Bought in Q4 2019, sold in Q3 2020 - Estimated return: 278.41% - Company profit growth: 184.37% [6] - Example of Nanji E-commerce: - Bought in Q1 2019, sold in Q2 2020 - Estimated return: 70.27% - Company revenue growth: 6.78% [7] - Example of Huaheng Biological: - Bought in Q3 2022, sold in Q3 2024 - Estimated return: -39.35% - Company revenue growth: 53.52% [9]

Core Insights - Huaheng Biological (688639.SH) reported a total operating revenue of 2.194 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 42.53% [1] - The net profit attributable to shareholders of the parent company was 168 million yuan, showing a year-on-year decrease of 1.34% [1] - The basic earnings per share stood at 0.67 yuan [1]

Group 1 - The company announced the convening of its second employee representative assembly for 2025 on October 27, 2025 [1] - Mao Jianwen has been elected as the employee representative director of the company's fifth board of directors [1]

独立董事候选人声明与承诺 （二）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证券 交易所规定的情形。 三、本人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其配偶、 父母、子女、主要社会关系（主要社会关系是指兄弟姐妹、兄 弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子女的配偶、 子女配偶的父母等）； （二）直接或者间接持有上市公司已发行股份 1%以上或者 是上市公司前十名股东中的自然人股东及其配偶、父母、子女； （三）在直接或者间接持有上市公司已发行股份 5%以上的 股东或者在上市公司前五名股东任职的人员及其配偶、父母、 子女； 本人陈继忠，已充分了解并同意由提名人安徽华恒生物科 技股份有限公司董事会提名为安徽华恒生物科技股份有限公司 第五届董事会独立董事候选人。本人公开声明，本人具备独立 董事任职资格，保证不存在任何影响本人担任安徽华恒生物科 技股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、 ...

本人吴林，已充分了解并同意由提名人安徽华恒生物科技 股份有限公司董事会提名为安徽华恒生物科技股份有限公司第 五届董事会独立董事候选人。本人公开声明，本人具备独立董 事任职资格，保证不存在任何影响本人担任安徽华恒生物科技 股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、部门规章及其他规范性文件，具有 5 年以上法律、 经济、会计、财务、管理或者其他履行独立董事职责所必需的 工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以 及公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证券 交易所规定的情形。 三、本人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其配偶、 父母、子女、主要社会关系（主要社会关系是指兄弟姐妹、兄 弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子女的配偶、 独立董事候选人声明与承诺 子女配偶的父 ...

独立董事提名人声明与承诺 提名人安徽华恒生物科技股份有限公司董事会，现提名 WANG FUCAI（王富才）先生为安徽华恒生物科技股份有限公 司第五届董事会独立董事候选人，并已充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼职、有无重大失信等不 良记录等情况。被提名人已同意出任安徽华恒生物科技股份有 限公司第五届董事会独立董事候选人（参见该独立董事候选人 声明）。提名人认为，被提名人具备独立董事任职资格，与安徽 华恒生物科技股份有限公司之间不存在任何影响其独立性的关 系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法 律、行政法规、规章及其他规范性文件，具有 5 年以上法律、 经济、会计、财务、管理或者其他履行独立董事职责所必需的 工作经验。 二、被提名人任职资格符合下列法律、行政法规和部门规 章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证券 交易所规定的情形。 三、被提名人具备独 ...

关于选举第五届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届董事会任期 即将届满，根据《中华人民共和国公司法》（以下简称《公司法》）《上海证 券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第1号——规范运作》等法律法规、规范性文件以及《公司章程》等规定，公 司于2025年10月27日召开了2025年第二次职工代表大会，选举MAO JIANWEN （毛建文）先生为公司第五届董事会职工代表董事，与公司2025年第三次临时 股东会选举产生的董事共同组成公司第五届董事会，任期与公司第五届董事会 任期一致。上述第五届董事会职工代表董事简历详见附件。 上述职工代表董事符合相关法律、行政法规、规范性文件对董事任职资格 的要求，不存在《公司法》《公司章程》规定的不得担任公司董事的情形，未 曾受到中国证监会的行政处罚或证券交易所惩戒，不存在证券交易所公开认定 为不适合担任上市公司董事的情形。 证券代码:688639 证券简称:华恒生物 ...

安徽华恒生物科技股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688639 证券简称：华恒生物 公告编号：2025-048 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届董事会任期即 将届满，根据《中华人民共和国公司法》（以下简称《公司法》）《上海证券交易 所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》等法律法规、规范性文件以及《公司章程》等规定，公司开展董 事会换届选举工作。现将相关情况公告如下： 一、董事会换届选举情况 公司于 2025 年 10 月 27 日召开第四届董事会第二十四次会议，审议通过《关 于选举公司第五届董事会非独立董事的议案》及《关于选举公司第五届董事会独 立董事的议案》，同意提名郭恒华女士、郭恒平先生、张学礼先生、张冬竹先生、 樊义先生为公司第五届董事会非独立董事候选人；同时同意提名陈继忠先生、吴 林先生、WANG FUCAI（王富才）先生为公司第五届董事会独立董事候选人。 独立董事候选人陈继忠先 ...